Personalized timing of surgery for advanced ovarian cancer
Treatments studied
Part of Cancer, Hormones & metabolism, Women’s health & pregnancy clinical trials.
This trial checks if adjusting the timing of surgery (interval debulking surgery) after chemotherapy can improve outcomes for people with advanced ovarian cancer. It's for those who cannot have surgery right away and will receive chemotherapy first.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are 18 or older
- You have advanced ovarian, fallopian tube, or primary peritoneal cancer that can't be removed with surgery right away
- You are planning to get chemotherapy before surgery (neoadjuvant chemotherapy)
- Your CA125 blood test level is at least twice the normal amount
- You are willing to have surgery at a time that may be different from the usual plan
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study looks at whether the timing of surgery after chemotherapy can be personalized for advanced ovarian cancer. It uses a blood test (CA125) to help decide the best time for surgery, aiming to improve outcomes.
This trial checks whether having surgery to remove as much tumor as possible, followed by ongoing targeted treatment, helps people with advanced ovarian (and related) cancers live longer and/or control cancer better. It specifically uses tumor-testing results to match patients and then continues treatment after surgery.
This study tests whether monitoring a tumor marker called KELIM can help doctors decide the best time for surgery in people with advanced ovarian, fallopian tube, or primary peritoneal cancer. Participants first receive chemotherapy to shrink tumors, then have surgery either at a planned time or later based on how the tumor marker changes.
This study looks at how well a minimally invasive surgery (laparoscopic debulking) can remove tumor in people with advanced epithelial ovarian cancer. It may help doctors compare whether this approach is safe and effective for patients who need either upfront surgery or surgery after chemotherapy.
This trial compares two ways of treating advanced ovarian cancer: having surgery first, or having chemotherapy first followed by surgery. The goal is to see which approach improves outcomes for patients.
This trial is testing a combination of two new immunotherapy drugs (iparomlimab and tuvonralimab) given before surgery and together with chemotherapy for advanced ovarian cancer. It aims to see if this approach can shrink the cancer more effectively and improve outcomes.
Hear when a new Ovarian cancer trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.